August 2025
1. DINARDO CD, Marvin-Peek J, Loghavi S, Takahashi K, et al
   Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML.
   J Clin Oncol. 2025;43:2692-2699.
   

   >> Share

   
   
2. PLATZBECKER U, Ades L, Montesinos P, Ammatuna E, et al
   Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.
   J Clin Oncol. 2025 Aug 18:JCO2500535. doi: 10.1200/JCO-25-00535.
   

   >> Share

   
   
3. ILAND HJ
   APOLLO: Optimizing the Treatment of High-Risk Acute Promyelocytic Leukemia With All-Trans Retinoic Acid and Arsenic Trioxide While Minimizing the Role of Chemotherapy.
   J Clin Oncol. 2025 Aug 18:JCO2501496. doi: 10.1200/JCO-25-01496.
   

   >> Share

   
   
4. ZEIDNER JF, Lin TL, Welkie RL, Curran E, et al
   Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.
   J Clin Oncol. 2025;43:2606-2615.
   

   >> Share

   
   July 2025
5. SHARMAN JP, Munir T, Grosicki S, Roeker LE, et al
   Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
   J Clin Oncol. 2025 Jul 29:JCO2501700. doi: 10.1200/JCO-25-01700.
   

   >> Share

   
   June 2025
6. SHARMAN JP, Munir T, Grosicki S, Roeker LE, et al
   Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
   J Clin Oncol. 2025 Jun 27:JCO2501356. doi: 10.1200/JCO-25-01356.
   

   >> Share

   
   
7. HUANG BJ, Meyer LK, Alonzo TA, Wang YC, et al
   Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group.
   J Clin Oncol. 2025;43:1961-1971.
   

   >> Share

   
   
8. SHARMAN JP, Munir T, Grosicki S, Roeker LE, et al
   Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
   J Clin Oncol. 2025 Jun 6:JCO2500166. doi: 10.1200/JCO-25-00166.
   

   >> Share

   
   May 2025
9. SHADMAN M, Munir T, Ma S, Lasica M, et al
   Zanubrutinib and Venetoclax for Patients With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results.
   J Clin Oncol. 2025 May 31:JCO2500758. doi: 10.1200/JCO-25-00758.
   

   >> Share

   
   April 2025
10. KIRKWOOD AA, Goulden N, Moppett J, Samarasinghe S, et al
    High-Dose Methotrexate in Children and Young Adults With ALL and Lymphoblastic Lymphoma: Results of the Randomized Phase III Study UKALL 2011.
    J Clin Oncol. 2025 Apr 7:JCO2401851. doi: 10.1200/JCO-24-01851.
    

    >> Share

    
    March 2025
11. DAVIDS MS, Ryan CE, Lampson BL, Ren Y, et al
    Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naive Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
    J Clin Oncol. 2025 Mar 18:JCO2500466. doi: 10.1200/JCO-25-00466.
    

    >> Share

    
    
12. TREGNAGO C, Benetton M, Ries RE, Peplinski JH, et al
    Influence of Nucleophosmin (NPM1) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration.
    J Clin Oncol. 2025;43:972-984.
    

    >> Share

    
    February 2025
13. RUSSELL NH, Thomas A, Hills RK, Thomas I, et al
    Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.
    J Clin Oncol. 2025;43:694-704.
    

    >> Share

    
    
14. KATO M, Okamoto Y, Imamura T, Kada A, et al
    JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL.
    J Clin Oncol. 2025;43:567-577.
    

    >> Share

    
    
15. ROLOFF GW, Aldoss I, Kopmar NE, Lin C, et al
    Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
    J Clin Oncol. 2025;43:558-566.
    

    >> Share

    
    January 2025
16. GYURKOCZA B, Nath R, Seropian S, Choe H, et al
    Randomized Phase III SIERRA Trial of (131)I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
    J Clin Oncol. 2025;43:201-213.
    

    >> Share

    
    December 2024
17. KANTARJIAN H, Short NJ, Haddad FG, Jain N, et al
    Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL.
    J Clin Oncol. 2024;42:4246-4251.
    

    >> Share

    
    
18. ROY A, Brander DM, Hill EG, Halabi S, et al
    Statistical Perspectives and Meta-Analytic Approaches in Surrogate End Point Evaluation for Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2024 Dec 12:JCO2401881. doi: 10.1200/JCO-24-01881.
    

    >> Share

    
    
19. SHADMAN M, Munir T, Robak T, Brown JR, et al
    Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.
    J Clin Oncol. 2024 Dec 8:JCO2402265. doi: 10.1200/JCO-24-02265.
    

    >> Share

    
    
20. DAVIDS MS, Ryan CE, Lampson BL, Ren Y, et al
    Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naive Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
    J Clin Oncol. 2024 Dec 7:JCO2402503. doi: 10.1200/JCO-24-02503.
    

    >> Share

    
    
21. VERSLUIS J, Metzner M, Wang A, Gradowska P, et al
    Risk Stratification in Older Intensively Treated Patients With AML.
    J Clin Oncol. 2024;42:4084-4094.
    

    >> Share

    
    November 2024
22. LANGERBEINS P, Robrecht S, Nieper P, Cramer P, et al
    Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.
    J Clin Oncol. 2024 Nov 27:JCO2400975. doi: 10.1200/JCO.24.00975.
    

    >> Share

    
    
23. HEIKAMP EB, Armstrong SA
    Revumenib Revises the Treatment Landscape for KMT2A-r Leukemia.
    J Clin Oncol. 2024 Nov 7:JCO2401265. doi: 10.1200/JCO-24-01265.
    

    >> Share

    
    October 2024
24. CHEVALLIER P, Leguay T, Delord M, Salek C, et al
    Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22(+) Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2024 Oct 17:JCO2400490. doi: 10.1200/JCO.24.00490.
    

    >> Share

    
    September 2024
25. ROLLIG C, Steffen B, Schliemann C, Mikesch JH, et al
    Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia.
    J Clin Oncol. 2024 Sep 16:JCO2400235. doi: 10.1200/JCO.24.00235.
    

    >> Share

    
    
26. KIM R, Chalandon Y, Rousselot P, Cayuela JM, et al
    Significance of Measurable Residual Disease in Adult Philadelphia Chromosome-Positive ALL: A GRAAPH-2014 Study.
    J Clin Oncol. 2024;42:3140-3150.
    

    >> Share

    
    
27. VALLEJO BA, Ansari A, Parikh SA, Achenbach SJ, et al
    Risk of Incident Melanoma Among Individuals With Low-Count Monoclonal B-Cell Lymphocytosis.
    J Clin Oncol. 2024 Sep 4:JCO2400332. doi: 10.1200/JCO.24.00332.
    

    >> Share

    
    August 2024
28. SIMON F, Ligtvoet R, Robrecht S, Cramer P, et al
    Endpoint Surrogacy in First-Line Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2024 Aug 30:JCO2401192. doi: 10.1200/JCO.24.01192.
    

    >> Share

    
    
29. CHANG TC, Chen W, Qu C, Cheng Z, et al
    Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2024 Aug 9:JCO2302238. doi: 10.1200/JCO.23.02238.
    

    >> Share

    
    
30. ISSA GC, Aldoss I, Thirman MJ, DiPersio J, et al
    Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
    J Clin Oncol. 2024 Aug 9:JCO2400826. doi: 10.1200/JCO.24.00826.
    

    >> Share

    
    
31. YOSHIMURA S, Li Z, Gocho Y, Yang W, et al
    Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2024 Aug 5:JCO2400500. doi: 10.1200/JCO.24.00500.
    

    >> Share

    
    
32. TURCOTTE LM, Neglia JP
    Duress and Distress Versus a Neurocognitive Mess: The Challenges of Procedural Sedation in Pediatric B-ALL.
    J Clin Oncol. 2024;42:2628-2631.
    

    >> Share

    
    
33. ALEXANDER S, Kairalla JA, Gupta S, Hibbitts E, et al
    Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk B ALL: A Children's Oncology Group Study.
    J Clin Oncol. 2024;42:2671-2679.
    

    >> Share

    
    July 2024
34. MATAVA CT, Peyton J, von Ungern-Sternberg BS, Ing C, et al
    Propofol, Anesthesia, and Neurocognitive Outcomes in Patients With Pediatric Leukemia: Are We Missing the Forest for the Trees?
    J Clin Oncol. 2024 Jul 24:JCO2400856. doi: 10.1200/JCO.24.00856.
    

    >> Share

    
    June 2024
35. TIERENS A, Arad-Cohen N, Cheuk D, De Moerloose B, et al
    Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease.
    J Clin Oncol. 2024;42:2174-2185.
    

    >> Share

    
    
36. TIONG IS, Hiwase DK, Abro E, Bajel A, et al
    Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC).
    J Clin Oncol. 2024;42:2161-2173.
    

    >> Share

    
    
37. KITTAI AS, Bond D, Huang Y, Bhat SA, et al
    Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.
    J Clin Oncol. 2024;42:2071-2079.
    

    >> Share

    
    
38. REED DR, Tulpule A, Metts J, Trucco M, et al
    Pediatric Leukemia Roadmaps Are a Guide for Positive Metastatic Bone Sarcoma Trials.
    J Clin Oncol. 2024 Jun 6:JCO2302717. doi: 10.1200/JCO.23.02717.
    

    >> Share

    
    May 2024
39. DAVER NG, Craddock C
    Moving Toward Total Therapy in AML: Personalized Treatments Improve Post-Transplant Outcome.
    J Clin Oncol. 2024;42:1731-1733.
    

    >> Share

    
    
40. WANG ES, Goldberg AD, Tallman M, Walter RB, et al
    Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML.
    J Clin Oncol. 2024;42:1776-1787.
    

    >> Share

    
    
41. VAN DER SLUIS IM, Brigitha LJ, Fiocco M, de Groot-Kruseman HA, et al
    Continuous PEGasparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric ALL: A Dutch Childhood Oncology Group ALL11 Randomized Trial.
    J Clin Oncol. 2024;42:1676-1686.
    

    >> Share

    
    
42. SHORT NJ, Daver N, Dinardo CD, Kadia T, et al
    Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.
    J Clin Oncol. 2024;42:1499-1508.
    

    >> Share

    
    April 2024
43. TOBIASSON M, Pandzic T, Illman J, Nilsson L, et al
    Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.
    J Clin Oncol. 2024;42:1378-1390.
    

    >> Share

    
    
44. RUSSELL NH, Wilhelm-Benartzi C, Othman J, Dillon R, et al
    Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.
    J Clin Oncol. 2024;42:1158-1168.
    

    >> Share

    
    March 2024
45. BERMAN E, Shah NP, Deninger M, Altman JK, et al
    CML and the WHO: Why?
    J Clin Oncol. 2024;42:984-986.
    

    >> Share

    
    
46. FEDELE PL, Opat S
    Chronic Lymphocytic Leukemia-Time to Care for the Survivors.
    J Clin Oncol. 2024 Mar 15:JCO2302738. doi: 10.1200/JCO.23.02738.
    

    >> Share

    
    
47. LEVIS MJ, Hamadani M, Logan B, Jones RJ, et al
    Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3.
    J Clin Oncol. 2024 Mar 12:JCO2302474. doi: 10.1200/JCO.23.02474.
    

    >> Share

    
    
48. MAHON FX, Pfirrmann M, Dulucq S, Hochhaus A, et al
    European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.
    J Clin Oncol. 2024 Mar 12:JCO2301647. doi: 10.1200/JCO.23.01647.
    

    >> Share

    
    
49. FOA R, Bassan R, Elia L, Piciocchi A, et al
    Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL.
    J Clin Oncol. 2024;42:881-885.
    

    >> Share

    
    
50. CONTER V, Valsecchi MG, Cario G, Zimmermann M, et al
    Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study.
    J Clin Oncol. 2024;42:915-926.
    

    >> Share

    
    
51. HODDER A, Mishra AK, Enshaei A, Baird S, et al
    Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL.
    J Clin Oncol. 2024;42:907-914.
    

    >> Share

    
    January 2024
52. LOGAN A
    Innovating Simpler and Less Toxic Frontline Management for Adults With ALL.
    J Clin Oncol. 2024;42:250-252.
    

    >> Share

    
    
53. STELLJES M, Raffel S, Alakel N, Wasch R, et al
    Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL.
    J Clin Oncol. 2024;42:273-282.
    

    >> Share

    
    
54. STINCHCOMBE TE, Wang X, Damman B, Mentlick J, et al
    Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2024 Jan 12:JCO2301306. doi: 10.1200/JCO.23.01306.
    

    >> Share

    
    December 2023
55. PIETERS R, Mullighan CG, Hunger SP
    Advancing Diagnostics and Therapy to Reach Universal Cure in Childhood ALL.
    J Clin Oncol. 2023;41:5579-5591.
    

    >> Share

    
    
56. LEE SHR, Ashcraft E, Yang W, Roberts KG, et al
    Prognostic and Pharmacotypic Heterogeneity of Hyperdiploidy in Childhood ALL.
    J Clin Oncol. 2023;41:5422-5432.
    

    >> Share

    
    
57. RASHIDI A, Ebadi M, Rehman TU, Elhusseini H, et al
    Randomized Double-Blind Phase II Trial of Fecal Microbiota Transplantation Versus Placebo in Allogeneic Hematopoietic Cell Transplantation and AML.
    J Clin Oncol. 2023;41:5306-5319.
    

    >> Share

    
    November 2023
58. BRIVIO E, Pennesi E, Willemse ME, Huitema ADR, et al
    Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921.
    J Clin Oncol. 2023 Nov 30:JCO2300897. doi: 10.1200/JCO.23.00897.
    

    >> Share

    
    
59. RAETZ EA, Rebora P, Conter V, Schrappe M, et al
    Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials.
    J Clin Oncol. 2023;41:5025-5034.
    

    >> Share

    
    
60. DAVER NG, Vyas P, Kambhampati S, Al Malki MM, et al
    Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.
    J Clin Oncol. 2023;41:4893-4904.
    

    >> Share

    
    
61. LI J, Gao J, Liu A, Liu W, et al
    Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study.
    J Clin Oncol. 2023;41:4881-4892.
    

    >> Share

    
    October 2023
62. DEWOLF S, Tallman MS, Rowe JM, Salman MY, et al
    What Influences the Decision to Proceed to Transplant for Patients With AML in First Remission?
    J Clin Oncol. 2023;41:4693-4703.
    

    >> Share

    
    
63. LING Y, Xuan L, Xu N, Huang F, et al
    Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial.
    J Clin Oncol. 2023;41:4632-4642.
    

    >> Share

    
    September 2023
64. MCCAW ZR, Richardson PG, Wei LJ
    Assessing the Ability of Long Noncoding RNA Expression to Predict Patient Outcomes in Pediatric AML.
    J Clin Oncol. 2023;41:4446-4447.
    

    >> Share

    
    
65. 
    Erratum: Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol.
    J Clin Oncol. 2023 Sep 12:JCO2301844. doi: 10.1200/JCO.23.01844.
    

    >> Share

    
    
66. PRATZ KW, Cherry M, Altman JK, Cooper BW, et al
    Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.
    J Clin Oncol. 2023;41:4236-4246.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share